{
  "emaEpar": [],
  "fdaDrugLabel": [
    {
      "brand": "MEDROXYPROGESTERONE ACETATE",
      "indication": "1 INDICATIONS AND USAGE Medroxyprogesterone acetate injectable suspension is indicated for use by females of reproductive potential to prevent pregnancy. Limitations of Use: The use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see Dosage and Administration (2.1) and Warnings and Precautions (5.1)]. Medroxyprogesterone acetate is a progestin indicated for use by females of reproductive potential to prevent pregnancy. (1) Limitations of Use: The use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate. (1, 5.1)",
      "manufacturer": "Sun Pharmaceutical Industries, Inc.",
      "splSetId": "01e28bef-9758-40cf-a4ff-86ae9f4f5105"
    },
    {
      "brand": "medroxyprogesterone acetate",
      "indication": "INDICATIONS AND USAGE Medroxyprogesterone acetate tablets are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.",
      "manufacturer": "PD-Rx Pharmaceuticals, Inc.",
      "splSetId": "0930a471-6ff1-43a1-b3ea-948ca3f99d06"
    },
    {
      "brand": "Medroxyprogesterone Acetate",
      "indication": "INDICATIONS AND USAGE Medroxyprogesterone Acetate Tablets USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.",
      "manufacturer": "Proficient Rx LP",
      "splSetId": "0df6fd1e-7d9c-4a38-848c-1e562e211c91"
    },
    {
      "brand": "Medroxyprogesterone",
      "indication": "INDICATIONS AND USAGE Medroxyprogesterone Acetate Tablets USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.",
      "manufacturer": "PharmPak, Inc.",
      "splSetId": "1403a9a9-c04a-432f-8819-4850f779312e"
    },
    {
      "brand": "Depo-Provera",
      "indication": "1 INDICATIONS AND USAGE Depo-Provera CI is indicated for use by females of reproductive potential to prevent pregnancy. Depo-Provera CI is a progestin indicated for use by females of reproductive potential to prevent pregnancy. ( 1 ) Limitations of Use: The use of Depo-Provera CI is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate. ( 1 , 5.1 ) Limitations of Use : The use of Depo-Provera CI is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see Dosage and Administration (2.1) and Warnings and Precautions (5.1) ].",
      "manufacturer": "Pharmacia & Upjohn Company LLC",
      "splSetId": "199cf13e-0859-4a73-9b45-e700d0cd1049"
    },
    {
      "brand": "medroxyprogesterone acetate",
      "indication": "INDICATIONS AND USAGE Medroxyprogesterone acetate tablets are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.",
      "manufacturer": "PD-Rx Pharmaceuticals, Inc.",
      "splSetId": "20c0841f-740c-4d53-af55-938c4e5b09e5"
    },
    {
      "brand": "medroxyprogesterone acetate",
      "indication": "INDICATIONS AND USAGE Medroxyprogesterone acetate tablets are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.",
      "manufacturer": "Greenstone LLC",
      "splSetId": "2627eb11-06bf-4a45-9172-094468e3ca07"
    },
    {
      "brand": "Medroxyprogesterone Acetate",
      "indication": "INDICATIONS AND USAGE Medroxyprogesterone Acetate Tablets USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.",
      "manufacturer": "Preferred Pharmaceuticals, Inc.",
      "splSetId": "37275fd0-eb24-40a4-a93f-b818bb98414e"
    },
    {
      "brand": "Depo-SubQ Provera",
      "indication": "1 INDICATIONS AND USAGE Depo-subQ provera 104 is indicated in females of reproductive age for: Prevention of pregnancy and Management of endometriosis-associated pain. Depo-subQ provera 104 is a progestin that is indicated in females of reproductive age for: Prevention of pregnancy. ( 1 ) Management of endometriosis-associated pain. ( 1 ) Limitations of Use : Use of depo-subQ provera 104 is not recommended as a long-term (i.e., longer than 2 years) birth control method or medical therapy for endometriosis-associated pain unless other options are considered inadequate. ( 1 , 5.1 ) Limitations of Use : The use of depo-subQ provera 104 is not recommended as a long-term (i.e., longer than 2 years) birth control method or medical therapy for endometriosis-associated pain unless other options are considered inadequate [see Dosage and Administration (2.1) and Warnings and Precautions (5.1) ].",
      "manufacturer": "Pharmacia & Upjohn Company LLC",
      "splSetId": "390087a6-f3c3-4f0b-a930-79acf412f153"
    },
    {
      "brand": "Prempro",
      "indication": "1 INDICATIONS AND USAGE PREMPRO/PREMPHASE is an estrogen plus progestin indicated in a woman with a uterus for: Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) Prevention of Postmenopausal Osteoporosis ( 1.3 ) 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause 1.3 Prevention of Postmenopausal Osteoporosis",
      "manufacturer": "A-S Medication Solutions",
      "splSetId": "3aff3442-641c-4639-8273-cf0347d8e4c8"
    },
    {
      "brand": "MEDROXYPROGESTERONE ACETATE",
      "indication": "1 INDICATIONS AND USAGE Medroxyprogesterone acetate injectable suspension is indicated for use by females of reproductive potential to prevent pregnancy. Limitations of Use: The use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see Dosage and Administration ( 2.1 ) and Warnings and Precautions ( 5.1 )]. Medroxyprogesterone acetate is a progestin indicated for use by females of reproductive potential to prevent pregnancy. ( 1 ) Limitations of Use: The use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate. ( 1 , 5.1 )",
      "manufacturer": "Cipla USA Inc.",
      "splSetId": "3d033fba-6313-4906-9d34-245423eaeeef"
    },
    {
      "brand": "Medroxyprogesterone Acetate",
      "indication": "INDICATIONS AND USAGE Medroxyprogesterone Acetate Tablets USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.",
      "manufacturer": "RedPharm Drug, Inc.",
      "splSetId": "419479ee-c1e1-306c-e054-00144ff8d46c"
    },
    {
      "brand": "medroxyprogesterone acetate",
      "indication": "1 INDICATIONS AND USAGE Medroxyprogesterone Acetate (MPA) Injectable Suspension, USP is indicated for use by females of reproductive potential to prevent pregnancy. Medroxyprogesterone Acetate (MPA) Injectable Suspension, USP is a progestin indicated for use by females of reproductive potential to prevent pregnancy. ( 1 ) Limitations of Use : The use of MPA Injectable Suspension, USP is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate. ( 1 , 5.1 ) Limitations of Use : The use of MPA Injectable Suspension, USP is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see Dosage and Administration (2.1) and Warnings and Precautions (5.1) ].",
      "manufacturer": "Greenstone LLC",
      "splSetId": "428481bb-b7cf-4d76-b57d-0d6bfa2b6ac3"
    },
    {
      "brand": "Medroxyprogesterone Acetate",
      "indication": "INDICATIONS AND USAGE Medroxyprogesterone Acetate Tablets USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.",
      "manufacturer": "PD-Rx Pharmaceuticals, Inc.",
      "splSetId": "437edd12-2c08-4df4-8cf7-64c47e4779ac"
    },
    {
      "brand": "Medroxyprogesterone Acetate",
      "indication": "INDICATIONS AND USAGE Medroxyprogesterone Acetate Tablets USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.",
      "manufacturer": "NuCare Pharmaceuticals,Inc.",
      "splSetId": "59cdc070-b4a2-1502-e053-2a91aa0a34fa"
    },
    {
      "brand": "Medroxyprogesterone Acetate",
      "indication": "INDICATIONS AND USAGE Medroxyprogesterone Acetate Tablets USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.",
      "manufacturer": "NuCare Pharmaceuticals,Inc.",
      "splSetId": "5c8ffae3-3b3e-197e-e053-2a91aa0a59e3"
    },
    {
      "brand": "Medroxyprogesterone Acetate",
      "indication": "1 INDICATIONS AND USAGE Medroxyprogesterone acetate injectable suspension is indicated only for the prevention of pregnancy. The loss of bone mineral density (BMD) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in BMD that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use medroxyprogesterone acetate injectable suspension long-term [ see Warnings and Precautions (5.1) ]. \u2022 Medroxyprogesterone acetate injectable suspension is a progestin indicated only for the prevention of pregnancy. ( 1 )",
      "manufacturer": "Mylan Institutional LLC",
      "splSetId": "60aba812-59eb-4d40-9b6b-d135dca9d36b"
    },
    {
      "brand": "Medroxyprogesterone Acetate",
      "indication": "INDICATIONS AND USAGE Medroxyprogesterone Acetate Tablets USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.",
      "manufacturer": "PD-Rx Pharmaceuticals, Inc.",
      "splSetId": "6a541749-5d14-44aa-a409-5e51f5bbf929"
    },
    {
      "brand": "Medroxyprogesterone Acetate",
      "indication": "INDICATIONS AND USAGE Medroxyprogesterone Acetate Tablets USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.",
      "manufacturer": "A-S Medication Solutions",
      "splSetId": "788df737-e990-4b5e-accd-af13c3b2bf8b"
    },
    {
      "brand": "MEDROXYPROGESTERONE ACETATE",
      "indication": "1 INDICATIONS AND USAGE Medroxyprogesterone acetate injectable suspension for use by females of reproductive potential to prevent pregnancy. Limitations of Use: The use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see Dosage and Administration (2.1) and Warnings and Precautions (5.1)]. Medroxyprogesterone acetate for use by females of reproductive potential to prevent pregnancy. (1) Limitations of Use: The use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate. (1, 5.1)",
      "manufacturer": "NorthStar RxLLC",
      "splSetId": "7cc31691-8268-4e59-b645-19246931f03c"
    },
    {
      "brand": "Medroxyprogesterone Acetate",
      "indication": "1 INDICATIONS AND USAGE Medroxyprogesterone acetate is indicated only for the prevention of pregnancy. The loss of bone mineral density (BMD) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in BMD that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use Medroxyprogesterone acetate long-term [see Warnings and Precautions (5.1) ] . Medroxyprogesterone acetate is a progestin indicated only for the prevention of pregnancy. ( 1 )",
      "manufacturer": "NuCare Pharmaceuticals,Inc.",
      "splSetId": "7cff8b17-0468-68ba-e053-2991aa0af484"
    },
    {
      "brand": "Medroxyprogesterone Acetate",
      "indication": "INDICATIONS AND USAGE Medroxyprogesterone Acetate Tablets USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.",
      "manufacturer": "A-S Medication Solutions",
      "splSetId": "816b9fd2-bc55-496b-846a-cabe7bbdecd6"
    },
    {
      "brand": "MEDROXYPROGESTERONE ACETATE",
      "indication": "1 INDICATIONS AND USAGE Medroxyprogesterone acetate injectable suspension for use by females of reproductive potential to prevent pregnancy. Limitations of Use: The use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see Dosage and Administration (2.1) and Warnings and Precautions (5.1)]. Medroxyprogesterone acetate for use by females of reproductive potential to prevent pregnancy. (1) Limitations of Use: The use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate. (1, 5.1)",
      "manufacturer": "Afaxys Pharma, LLC",
      "splSetId": "908573ce-d494-4f7f-95ae-6edbc4e4c5dc"
    },
    {
      "brand": "Medroxyprogesterone Acetate",
      "indication": "INDICATIONS AND USAGE Medroxyprogesterone Acetate Tablets USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.",
      "manufacturer": "Bryant Ranch Prepack",
      "splSetId": "93b7c9e8-fa4a-4b6f-879f-d71fd251e349"
    },
    {
      "brand": "Medroxyprogesterone Acetate",
      "indication": "1 INDICATIONS AND USAGE Medroxyprogesterone Acetate Injectable Suspension is indicated only for the prevention of pregnancy. The loss of bone mineral density (BMD) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in BMD that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use Medroxyprogesterone Acetate Injectable Suspension long-term [ see Warnings and Precautions ( 5.1 ) ]. \u2022 Medroxyprogesterone Acetate Injectable Suspension is a progestin indicated only for the prevention of pregnancy. ( 1 )",
      "manufacturer": "Proficient Rx LP",
      "splSetId": "9451ca1a-34a4-46e2-bacc-6268a2f60bc8"
    },
    {
      "brand": "Medroxyprogesterone Acetate",
      "indication": "INDICATIONS AND USAGE Medroxyprogesterone Acetate Tablets USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.",
      "manufacturer": "Teva Pharmaceuticals USA, Inc.",
      "splSetId": "9eb200b0-db96-4a51-87ea-04db862978c8"
    },
    {
      "brand": "Provera",
      "indication": "INDICATIONS AND USAGE PROVERA tablets are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.",
      "manufacturer": "Pharmacia and Upjohn Company LLC",
      "splSetId": "a586be28-96af-4fed-a13f-9b94fd4c7405"
    },
    {
      "brand": "Medroxyprogesterone Acetate",
      "indication": "1 INDICATIONS AND USAGE Medroxyprogesterone acetate is indicated only for the prevention of pregnancy. The loss of bone mineral density (BMD) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in BMD that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use Medroxyprogesterone acetate long-term [see Warnings and Precautions (5.1) ] . Medroxyprogesterone acetate is a progestin indicated only for the prevention of pregnancy. ( 1 )",
      "manufacturer": "A-S Medication Solutions",
      "splSetId": "a67023c9-9927-4333-aa88-00804db36570"
    },
    {
      "brand": "Medroxyprogesterone Acetate",
      "indication": "INDICATIONS AND USAGE Medroxyprogesterone Acetate Tablets USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.",
      "manufacturer": "Denton Pharma, Inc. dba Northwind Pharmaceuticals",
      "splSetId": "ab82d81a-fb06-ff34-e053-2a95a90a12ef"
    },
    {
      "brand": "Medroxyprogesterone Acetate",
      "indication": "INDICATIONS AND USAGE Medroxyprogesterone Acetate Tablets USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.",
      "manufacturer": "Bryant Ranch Prepack",
      "splSetId": "bdb89690-ced2-48e1-bb1a-e5eccfeda8eb"
    },
    {
      "brand": "Medroxyprogesterone Acetate",
      "indication": "INDICATIONS AND USAGE Medroxyprogesterone Acetate Tablets USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.",
      "manufacturer": "A-S Medication Solutions",
      "splSetId": "bfdf335d-1cbb-4533-9fde-99a9c71f7504"
    },
    {
      "brand": "Depo-Provera",
      "indication": "1 INDICATIONS AND USAGE Depo-Provera CI is indicated only for the prevention of pregnancy. The loss of bone mineral density (BMD) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in BMD that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use Depo-Provera CI long-term [ see Warnings and Precautions (5.1) ]. Depo-Provera CI is a progestin indicated only for the prevention of pregnancy. ( 1 )",
      "manufacturer": "A-S Medication Solutions",
      "splSetId": "c91f0af4-1411-4ab6-8b3c-b8dcfa56a9b7"
    },
    {
      "brand": "Medroxyprogesterone Acetate",
      "indication": "INDICATIONS AND USAGE Medroxyprogesterone Acetate Tablets USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.",
      "manufacturer": "American Health Packaging",
      "splSetId": "cbf142f9-9af3-4d79-9343-0ab42d6dbe9f"
    },
    {
      "brand": "Medroxyprogesterone Acetate",
      "indication": "INDICATIONS AND USAGE Medroxyprogesterone Acetate Tablets USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.",
      "manufacturer": "RPK Pharmaceuticals, Inc.",
      "splSetId": "ceccfb43-ad89-482d-9564-5867df1c936f"
    },
    {
      "brand": "MEDROXYPROGESTERONE ACETATE",
      "indication": "1 INDICATIONS AND USAGE Medroxyprogesterone acetate injectable suspension is indicated for use by females of reproductive potential to prevent pregnancy. Limitations of Use: The use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see Dosage and Administration (2.1) and Warnings and Precautions (5.1)]. Medroxyprogesterone acetate is a progestin indicated for use by females of reproductive potential to prevent pregnancy. (1) Limitations of Use: The use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate. (1, 5.1)",
      "manufacturer": "Sun Pharmaceutical Industries, Inc.",
      "splSetId": "d1ea4098-6196-421f-b8e1-bcb31a061e04"
    },
    {
      "brand": "medroxyprogesterone acetate",
      "indication": "1 INDICATIONS AND USAGE Medroxyprogesterone Acetate (MPA) Injectable Suspension, USP is indicated only for the prevention of pregnancy. The loss of bone mineral density (BMD) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in BMD that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use MPA Injectable Suspension, USP long-term [see Warnings and Precautions (5.1) ] . Medroxyprogesterone Acetate (MPA) Injectable Suspension, USP is a progestin injectable contraceptive indicated only for the prevention of pregnancy. ( 1 )",
      "manufacturer": "REMEDYREPACK INC.",
      "splSetId": "d21979ec-271f-4e4a-8d4d-d561b8a0f563"
    },
    {
      "brand": "Medroxyprogesterone Acetate",
      "indication": "1 INDICATIONS AND USAGE Medroxyprogesterone Acetate Injectable Suspension is indicated for use by females of reproductive potential to prevent pregnancy. Limitations of Use : The use of Medroxyprogesterone Acetate Injectable Suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see Dosage and Administration (2.1) and Warnings and Precautions ( 5.1 )] . Medroxyprogesterone Acetate Injectable Suspension is a progestin indicated for use by females of reproductive potential to prevent pregnancy. ( 1 ) Limitations of Use: The use of Medroxyprogesterone Acetate Injectable Suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate. ( 1 , 5.1 )",
      "manufacturer": "Teva Parenteral Medicines, Inc.",
      "splSetId": "d279981c-e9e4-4989-bafb-1e184a6d3dd2"
    },
    {
      "brand": "medroxyprogesterone acetate",
      "indication": "1 INDICATIONS AND USAGE Medroxyprogesterone Acetate (MPA) Injectable Suspension, USP is indicated only for the prevention of pregnancy. The loss of bone mineral density (BMD) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in BMD that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use MPA Injectable Suspension, USP long-term [see Warnings and Precautions (5.1) ] . Medroxyprogesterone Acetate (MPA) Injectable Suspension, USP is a progestin injectable contraceptive indicated only for the prevention of pregnancy. ( 1 )",
      "manufacturer": "A-S Medication Solutions",
      "splSetId": "d415e7cc-0756-4c70-803f-011133a6b731"
    },
    {
      "brand": "medroxyprogesterone acetate",
      "indication": "INDICATIONS AND USAGE Medroxyprogesterone acetate tablets are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.",
      "manufacturer": "PD-Rx Pharmaceuticals, Inc.",
      "splSetId": "e1d5975a-e0e5-444d-bab0-3904c3f377c9"
    },
    {
      "brand": "Medroxyprogesterone Acetate",
      "indication": "1 INDICATIONS AND USAGE Medroxyprogesterone acetate is indicated only for the prevention of pregnancy. The loss of bone mineral density (BMD) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in BMD that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use Medroxyprogesterone acetate long-term [see Warnings and Precautions (5.1) ] . Medroxyprogesterone acetate is a progestin indicated only for the prevention of pregnancy. ( 1 )",
      "manufacturer": "Amphastar Pharmaceuticals, Inc.",
      "splSetId": "e364a31e-8926-4bda-b00e-efb097bd3830"
    },
    {
      "brand": "MEDROXYPROGESTERONE ACETATE",
      "indication": "1 INDICATIONS AND USAGE Medroxyprogesterone acetate injectable suspension is indicated for use by females of reproductive potential to prevent pregnancy. Limitations of Use: The use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see Dosage and Administration (2.1) and Warnings and Precautions (5.1)]. Medroxyprogesterone acetate is a progestin indicated for use by females of reproductive potential to prevent pregnancy. (1) Limitations of Use: The use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate. (1, 5.1)",
      "manufacturer": "NorthStar RxLLC",
      "splSetId": "f7629f1b-602d-47f9-947d-7ec5bc4ac8d0"
    },
    {
      "brand": "Prempro",
      "indication": "1 INDICATIONS AND USAGE PREMPRO/PREMPHASE is an estrogen plus progestin indicated in a woman with a uterus for: Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) Prevention of Postmenopausal Osteoporosis ( 1.3 ) 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause 1.3 Prevention of Postmenopausal Osteoporosis",
      "manufacturer": "Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.",
      "splSetId": "fd0c0836-5d23-2183-da81-9dc7f4287052"
    },
    {
      "brand": "Medroxyprogesterone Acetate",
      "indication": "1 INDICATIONS AND USAGE Medroxyprogesterone acetate is indicated only for the prevention of pregnancy. The loss of bone mineral density (BMD) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in BMD that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use Medroxyprogesterone acetate long-term [see Warnings and Precautions (5.1) ] . Medroxyprogesterone acetate is a progestin indicated only for the prevention of pregnancy. ( 1 )",
      "manufacturer": "Amphastar Pharmaceuticals, Inc.",
      "splSetId": "fda1aa8a-5739-482a-b4f6-9741ef4d9977"
    }
  ],
  "id": "Medroxyprogesterone_Acetate",
  "nciThesaurus": {
    "casRegistry": "71-58-9",
    "chebiId": "CHEBI:6716",
    "chemicalFormula": "C24H34O4",
    "definition": "A synthetic, acetate derivative of the sex hormone progesterone.  Medroxyprogesterone 17-acetate",
    "fdaUniiCode": "C2QI4IOI2G",
    "identifier": "C1155",
    "preferredName": "Medroxyprogesterone Acetate",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C776"
    ],
    "synonyms": [
      "(6alpha)-17-(Acetyloxy)-6-methylpregn-4-ene-3,20-dione",
      "17-(Acetyloxy)-6alpha-methylpregn-4-ene-3,20-dione",
      "17-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione Acetate",
      "17Alpha-acetoxy-6alpha-methylprogesterone",
      "6-Alpha-methyl-17alpha-acetoxyprogesterone",
      "Amen",
      "Aragest",
      "Ciclotal",
      "Clinofem",
      "Clinovir",
      "Cycrin",
      "Depo-Clinovir",
      "Depo-Provera",
      "Depo-provera",
      "Depot-Medroxyprogestereone Acetate",
      "Farlutal",
      "G-Farlutal",
      "Gestapuran",
      "Hysron",
      "Lutoral",
      "MEDROXYPROGESTERONE ACETATE",
      "MPA",
      "Medroxyprogesterone 17-Acetate",
      "Medroxyprogesterone Acetate",
      "Medroxyprogesterone acetate",
      "Medroxyprogesteroni Acetas",
      "Methylacetoxyprogesterone",
      "Metipregnone",
      "Nadigest",
      "Nadigest (vet)",
      "Nidaxin",
      "Nidaxin (vet)",
      "Oragest",
      "Perlutex",
      "Prodasone",
      "Provera",
      "Sodelut G",
      "Veramix",
      "medroxyprogesterone acetate"
    ]
  }
}